Neovasc Revenue and Competitors
Estimated Revenue & Valuation
- Neovasc's estimated annual revenue is currently $8.9M per year.
- Neovasc's estimated revenue per employee is $125,500
- Neovasc's total funding is $385.2M.
Employee Data
- Neovasc has 71 Employees.
- Neovasc grew their employee count by -14% last year.
Neovasc's People
Name | Title | Email/Phone |
---|---|---|
1 | VP Clinical Affairs | Reveal Email/Phone |
2 | VP Human Resources | Reveal Email/Phone |
3 | VP DACH | Reveal Email/Phone |
4 | Chief Quality Officer | Reveal Email/Phone |
5 | Medical Director | Reveal Email/Phone |
6 | Chief Operating Officer | Reveal Email/Phone |
7 | Quality Engineering Manager | Reveal Email/Phone |
8 | Clinical Study Manager | Reveal Email/Phone |
9 | Manager, Manufacturing | Reveal Email/Phone |
10 | Senior Manager, Quality | Reveal Email/Phone |
Neovasc Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $31.1M | 124 | -4% | N/A | N/A |
#2 | $4M | 16 | -6% | N/A | N/A |
#3 | $78.3M | 312 | 9% | N/A | N/A |
#4 | $23.1M | 92 | 6% | N/A | N/A |
#5 | $9.3M | 37 | 9% | N/A | N/A |
#6 | $75.3M | 240 | 3% | $53.9M | N/A |
#7 | $267.6M | 1066 | 13% | N/A | N/A |
#8 | $36.6M | 0 | N/A | $1.3B | N/A |
#9 | $30.9M | 123 | -20% | N/A | N/A |
#10 | $8.5M | 34 | -17% | N/A | N/A |
What Is Neovasc?
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer? for the treatment of refractory angina and the Tiara? technology in development for the transcatheter treatment of mitral valve disease. To receive Neovasc updates via email, please register at: http://www.neovasc.com/register.
keywords:N/A$385.2M
Total Funding
71
Number of Employees
$8.9M
Revenue (est)
-14%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Neovasc News
Neovasc is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular...
Neovasc is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular...
Healthcare Investment Conference to be held May 2-3, 2022. Fred Colen, Neovasc's Chief Executive Officer, will be presenting at 4:00 pm ET on...
Neovasc Inc. Management's Discussion and Analysis FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020 (Expressed in U.S. Dollars) Q3 2021 MANAGEMENT'S DISCUSSION AND ANALYSIS This Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") ...
Neovasc Announces Third Quarter 2021 Financial Results and Provides Corporate Update VANCOUVER and MINNEAPOLIS via NewMediaWire --Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today reported financial results for the third quarter ended September 30, 2021. Third Quarter Highl ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $15.9M | 72 | -5% | N/A |
#2 | $18.2M | 75 | 6% | N/A |
#3 | $20.5M | 76 | 7% | N/A |
#4 | $12M | 80 | 11% | N/A |
#5 | $26.7M | 82 | 5% | N/A |